Acadia Healthcare Company, Inc. (ACHC) 2024 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, and welcome to Acadia Healthcare's First Quarter of 2024 Earnings Call. (Operator Instructions) Also please be aware that today's call is being recorded. I would now like to turn the call over to Patrick Feeley, Head of Investor Relations. Please go ahead.

    各位好,歡迎參加 Acadia Healthcare 2024 年第一季財報電話會議。(接線員指示)另外請注意,今天的電話會議將被錄音。現在我想把電話交給投資人關係主管 Patrick Feeley。請開始。

  • Patrick Feeley

    Patrick Feeley

  • Thank you, and good morning. Yesterday after the market closed, we issued a press release announcing our First Quarter 2024 Financial Results. This press release can be found in the Investor Relations section of the acadiahealthcare.com website. Here with me today to discuss the results are Chris Hunter, Chief Executive Officer; and Heather Dixon, Chief Financial Officer.

    謝謝,各位早安。昨天收盤後,我們發布新聞稿,公布 2024 年第一季財務業績。該新聞稿可於 acadiahealthcare.com 網站的投資人關係專區查閱。今天與我一同討論結果的有執行長 Chris Hunter,以及財務長 Heather Dixon。

  • To the extent any non-GAAP financial measures is discussed on today's call, you will find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP in the press release that is posted on our website. This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2024 and beyond.

    若今天的電話會議中討論任何非 GAAP 財務衡量指標,您可在我們網站上發布的新聞稿中,找到該指標與依 GAAP 計算之最直接可比財務衡量指標的調節表。本次電話會議可能包含《1995 年私人證券訴訟改革法》所定義的前瞻性陳述,其中包括但不限於關於 Acadia 對 2024 年及其後預期之季度與年度財務表現的陳述。

  • You are hereby cautioned that these statements may be affected by important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and the company's first quarter news release and consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements.

    特此提醒您,這些陳述可能受到重要因素影響,包括但不限於 Acadia 向美國證券交易委員會提交之文件以及公司第一季新聞稿中所列因素;因此,實際營運與結果可能與前瞻性陳述中討論的結果存在重大差異。

  • At this time, I'd like to turn the conference call over to Chris for opening remarks.

    此時,我想把電話會議交給 Chris 發表開場致詞。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Thank you, Patrick, and good morning, everyone. Thank you for being with us for Acadia's First Quarter 2024 Conference Call. Before we get to the results, I want to note some recent key additions to our leadership team. He just introduced this call, but I want to officially welcome Patrick Feeley to Acadia as our new Senior Vice President of Investor Relations.

    謝謝你,Patrick,各位早安。感謝各位參加 Acadia 2024 年第一季電話會議。在進入業績之前,我想提及近期我們領導團隊的幾項重要新加入成員。他剛剛在電話中介紹了,但我想正式歡迎 Patrick Feeley 加入 Acadia,擔任我們新的投資人關係資深副總裁。

  • Patrick joins the company after leading Investor Relations for Teladoc Health. And prior to that, he spent several years in Health Care Equity Research covering the health care services sector. We want to also thank Gretchen Hommrich for her 8 years of dedicated service leading Investor Relations for Acadia.

    Patrick 在加入本公司前,曾負責 Teladoc Health 的投資人關係。在此之前,他也在醫療保健股票研究領域任職多年,涵蓋醫療服務產業。我們也要感謝 Gretchen Hommrich 在過去 8 年間領導 Acadia 投資人關係所提供的敬業服務。

  • In early April, we announced Dr. Stephanie Eken as Acadia's new Chief Medical Officer. A triple board-certified physician, Dr. Eken brings more than 2 decades of behavioral health care experience in a variety of settings. She joins Acadia after spending 15 years at Rogers Behavioral Health, a not-for-profit nationwide independent provider of specialized mental health and addiction treatment.

    4 月初,我們宣布 Stephanie Eken 醫師出任 Acadia 新任首席醫療官。Eken 醫師為三重專科委員會認證醫師,擁有超過 20 年在多元場域的行為健康照護經驗。她在加入 Acadia 前,於 Rogers Behavioral Health 任職 15 年;該機構為非營利、全國性且獨立的專業心理健康與成癮治療服務提供者。

  • At Rogers, she most recently served as Chief Medical Officer partnering with the systems executive leadership to lead patient care quality and facilities expansion. We look forward to working with Dr. Eken and benefiting from her experience and expertise.

    在 Rogers,她最近擔任首席醫療官,與系統層級的高階管理團隊合作,領導病患照護品質與院區擴張。我們期待與 Eken 醫師共事,並受益於她的經驗與專業。

  • We also want to thank Dr. Michael Genovese, who has served in this important role for Acadia since 2017. We're grateful for his dedicated service and are pleased that he will continue in a consulting role for the company and work with Dr. Eken as we make this transition.

    我們也要感謝 Michael Genovese 醫師,自 2017 年以來一直在 Acadia 擔任這項重要職務。我們感謝他長期的投入與服務,也很高興他將以顧問身分繼續為公司提供協助,並在交接過程中與 Eken 醫師合作。

  • Now turning to our first quarter results. Total revenue increased 9.1% over the prior year's first quarter to $768 million, driven by both rate improvement and patient day growth. Our top line growth, combined with strong operating leverage, drove adjusted EBITDA growth of 14.9% and adjusted EPS growth of 12.0%, as compared to the first quarter of 2023.

    接著談第一季業績。總營收較去年第一季成長 9.1% 至 7.68 億美元,主要由費率提升與病患日數成長共同帶動。我們的營收成長,加上強勁的營運槓桿,推動調整後 EBITDA 成長 14.9%,以及調整後每股盈餘(EPS)成長 12.0%,相較於 2023 年第一季。

  • We continue to be pleased with our progress on labor costs, improvements in the overall labor market combined with our continued efforts around hiring, retention and quality helped drive meaningful operating leverage and margin contribution in the first quarter. Those trends continue to give us a high level of confidence in our EBITDA outlook for the full year.

    我們對於人力成本方面的進展仍感到滿意。整體勞動市場改善,加上我們在招募、留任與品質方面持續努力,於第一季帶來顯著的營運槓桿與毛利率貢獻。這些趨勢持續讓我們對全年 EBITDA 展望保持高度信心。

  • On a same-store basis, revenue growth was strong, increasing 9.2% over the first quarter of last year. During the quarter, we experienced slightly weaker-than-anticipated same-store patient volumes. This was primarily driven by greater than typical seasonality due to the timing of spring break in Easter, which occurred in March of this year compared to April of last year.

    以同店基礎來看,營收成長強勁,較去年第一季增加 9.2%。本季我們的同店病患量略低於原先預期,主要原因是季節性影響高於往常,源於今年復活節與春假時間點的安排;今年復活節在 3 月,而去年則在 4 月。

  • While our first quarter outlook contemplated normal holiday seasonality around each of these events, the proximity of Easter to spring break resulted in an extended period of lower volumes through the back half of March. We also experienced weaker admissions towards the end of the quarter for our military specialty programs.

    雖然我們第一季展望已納入這些事件的正常假期季節性影響,但由於復活節與春假相距很近,導致 3 月下半月出現較長期間的低量。我們也在季度末看到軍方專科方案的入院人數較弱。

  • Given the strong underlying demand for our services in the broader marketplace, we're already well on our way towards rebuilding census at these facilities. Overall demand for our services remain strong, and we believe we are well positioned within our markets for continued growth, especially given the visibility we have with new beds coming online and ramping up over the course of the calendar year.

    鑑於更廣泛市場對我們服務的強勁基本需求,我們已在重建這些院區的住院人數(census)方面取得良好進展。整體而言,我們服務的需求仍然強勁;我們相信在各市場中具備持續成長的良好定位,尤其是考量到我們對於新床位於本曆年內陸續啟用並逐步爬坡的可見度。

  • Now I'd like to provide an update on each of our 5 defined growth pathways. For our first pathway Facility Expansions, we added 27 beds during the first quarter. We continue to expect to add more than 400 beds to existing facilities in 2024, a step up from our historical average of 300. These additions will be more heavily weighted toward the second half of the year.

    接下來我想就我們所定義的 5 大成長途徑逐一更新。第一個途徑「院區擴建(Facility Expansions)」方面,我們在第一季新增 27 張床位。我們仍預期 2024 年在既有院區新增超過 400 張床位,高於我們歷史平均的 300 張。這些新增床位將更集中於下半年。

  • For our second pathway, we remain focused on developing wholly owned De Novo Facilities in underserved markets for behavioral health care services. During the first quarter, we opened a 20-bed specialty facility, Sabal Palms Recovery Center located near Tampa, Florida, which will provide residential addiction treatment services. Additionally, planning is already underway for an expansion to this facility.

    第二個途徑方面,我們仍專注於在行為健康照護服務不足的市場,開發全資持有的全新設立院區(De Novo Facilities)。第一季期間,我們在佛羅里達州坦帕附近開設一間 20 床的專科機構 Sabal Palms Recovery Center,將提供住宿式成癮治療服務。此外,該院區的擴建規劃也已展開。

  • Following the end of the first quarter, Acadia opened a 100-bed acute care hospital, Agave Ridge Behavioral Hospital in Mesa, Arizona. We continue to plan to open up to 14 additional comprehensive treatment centers or CTCs in 2024. As a reminder, our CTC service line offers comprehensive care for patients who are affected by opioid use disorder or OUD.

    第一季結束後,Acadia 在亞利桑那州梅薩市開設一間 100 床的急性照護醫院 Agave Ridge Behavioral Hospital。我們仍計畫於 2024 年最多再開設 14 家綜合治療中心(CTC)。提醒各位,我們的 CTC 服務線提供針對受阿片類藥物使用障礙(OUD)影響之病患的整合式照護。

  • For our third growth pathway, we are working to expand our reach through our Joint Ventures. We're extremely proud to partner with premier health care systems across the country with a shared mission to expand behavioral health care in more communities. During the first quarter, we commenced construction on 2 new hospitals with previously announced partners.

    第三個成長途徑方面,我們正透過合資企業(Joint Ventures)擴大觸及範圍。我們非常自豪能與全國頂尖醫療體系合作,共同肩負在更多社區擴展行為健康照護的使命。第一季期間,我們與先前已公告的合作夥伴啟動 2 家新醫院的興建工程。

  • Acadia held groundbreaking ceremonies for a 144-bed behavioral health hospital in Apopka, Florida, in partnership with Orlando Health, as well as another 144-bed behavioral health hospital in Malden, Massachusetts, in partnership with Tufts Medicine. These facilities will expand much needed access to life-saving behavioral health services in their respective communities.

    Acadia 與 Orlando Health 合作,為位於佛羅里達州 Apopka 的 144 床行為健康醫院舉行動土典禮;同時也與 Tufts Medicine 合作,為位於麻薩諸塞州 Malden 的另一家 144 床行為健康醫院舉行動土典禮。這些院區將在各自社區擴大對攸關生命的行為健康服務之迫切所需的可近性。

  • Today, Acadia has 21 joint venture partnerships for 22 hospitals, with 11 hospitals already in operation and 11 additional hospitals expected to open over the next few years. Joint Ventures will continue to play an important role in Acadia's future growth and we are excited about the opportunities to work with other leading providers in attractive geographies.

    目前,Acadia 擁有 21 項合資合作關係、涵蓋 22 家醫院,其中 11 家已投入營運,另有 11 家預計在未來幾年內開幕。合資企業將持續在 Acadia 未來成長中扮演重要角色;我們也對於在具吸引力的地理區域與其他領先服務提供者合作的機會感到振奮。

  • For our fourth pathway, we continue to look for acquisitions that support our growth objectives and meet the criteria of our capital allocation strategy. During the quarter, we closed on the acquisition of Turning point Centers, a 76-bed specialty provider of substance abuse disorder and primary mental health care treatment services in Utah. At the end of the first quarter, we completed the acquisition of 3 CTCs in North Carolina, serving patients with OUD in Raleigh, Greenville, and Hillsborough and their respective surrounding communities.

    第四個途徑方面,我們持續尋找能支持成長目標、並符合我們資本配置策略標準的併購機會。本季我們完成收購 Turning Point Centers,該機構位於猶他州,為一家具 76 床的專科服務提供者,提供物質使用障礙與主要心理健康照護治療服務。第一季末,我們完成收購北卡羅來納州的 3 家 CTC,服務 OUD 病患,據點位於 Raleigh、Greenville 與 Hillsborough 及其周邊社區。

  • These acquisitions build upon our existing and strong clinical foundation within the state of North Carolina. North Carolina is a focus for Acadia to expand capacity and add additional sites of care given the state's immense need and progressive approach to behavioral health care treatment programs. With the addition of these 3 CTCs, Acadia now operates 10 CTC locations in North Carolina and 160 locations in 32 states across the country.

    這些併購進一步強化我們在北卡羅來納州既有且堅實的臨床基礎。北卡羅來納州是 Acadia 擴充產能並新增照護據點的重點州之一,因該州需求龐大,且對行為健康照護治療計畫採取較為前瞻的作法。隨著新增這 3 家 CTC,Acadia 目前在北卡羅來納州營運 10 個 CTC 據點,並在全國 32 州共營運 160 個據點。

  • As the opioid epidemic continues to intensify, we will continue to expand this important area of our business, as we see record demand for our CTC services. It's estimated that 9 million Americans are suffering from OUD and only about 10% of this group is in treatment for medication-assisted therapy, which is considered the gold standard for treatment.

    隨著阿片類藥物危機持續加劇,我們將持續擴展這項重要的業務領域,因為我們看到對我們 CTC 服務的需求創下新高。據估計,有 900 萬美國人正受 OUD 影響,而其中僅約 10% 正在接受藥物輔助治療(被視為治療的黃金標準)。

  • As we have previously discussed, the increasing prevalence of fentanyl mixed with other potent drugs has escalated the complexity and severity of OUD. We remain focused on meeting the critical demand for treatment by improving access to treatment, driving favorable clinical outcomes and delivering an exceptional patient experience.

    如我們先前所討論,芬太尼與其他強效藥物混用的盛行,已提高 OUD 的複雜性與嚴重性。我們仍專注於透過改善治療可近性、推動良好的臨床結果,並提供卓越的病患體驗,以滿足對治療的關鍵需求。

  • For our fifth growth pathway, extending the continuum of care remains important to our clinical strategy. One of the key focus areas of this pathway is expanding our partial hospitalization programs or PHPs in intensive outpatient programs, IOPs, that can provide 4 to 6 hours of care per day. These programs not only improve clinical outcomes, but also enhance the overall patient experience.

    就我們的第五項成長途徑而言,延伸照護連續體仍是我們臨床策略的重要一環。此途徑的關鍵聚焦領域之一,是擴大我們的部分住院計畫(PHP)與密集門診計畫(IOP),可提供每日 4 至 6 小時的照護。這些計畫不僅改善臨床結果,也提升整體病患體驗。

  • We added 15 outpatient programs during the first quarter of 2024, and we'll continue to focus on this important clinical service. As we continue to extend our market reach, patient safety and quality -- quality patient care remain top priorities for delivering the best possible outcome for our patients. Quality is foundational to every aspect of the work we do at Acadia and drives operational effectiveness.

    我們在 2024 年第一季新增了 15 個門診計畫,並將持續聚焦這項重要的臨床服務。隨著我們持續擴大市場觸及範圍,病患安全與品質——高品質的病患照護——仍是我們提供最佳可能治療結果的首要任務。品質是 Acadia 所做每一項工作的基礎,並驅動營運效能。

  • We continue to make investments in our quality programs that drive greater efficiency, including electronic medical records, patient monitoring technology and employee safety technology. We also recognize the importance of having quality measures and the right technology in place to make sure we're providing data that aligns with what our payers want to measure.

    我們持續投資於能提升效率的品質計畫,包括電子病歷、病患監測技術與員工安全技術。我們也認知到,必須具備品質衡量指標與適當技術,才能確保我們所提供的數據與付款方希望衡量的內容一致。

  • We expect to compete on the strength of our clinical outcomes, and the ability to measure and demonstrate these outcomes is important for our collaborations with payers. We're proud of the important work that we're doing. The demand for our behavioral health services across our nation has never been greater. Every demographic is affected by the lack of affordable access to behavioral health services, especially for the poor and elderly populations.

    我們預期將以臨床結果的優勢來競爭,而衡量並證明這些結果的能力,對我們與付款方的合作至關重要。我們以正在進行的重要工作為榮。全美對我們行為健康服務的需求從未如此之高。每個族群都受到缺乏可負擔行為健康服務可近性的影響,尤其是貧困與高齡族群。

  • While 1 in 5 adults have a mental illness, less than half of those received treatments. A recent report from the Office of the Inspector General or OIG found that about 1/3 of behavioral health providers in selected counties serve patients in the Medicare, Medicare Advantage or Medicaid programs. The shortage of providers also explains the lower use of the behavioral health system, with only 8% of Medicaid enrollees and less than 4% of Medicare and Medicare Advantage enrollees receiving behavioral health services.

    雖然每 5 位成人中就有 1 位患有精神疾病,但接受治療者不到一半。監察長辦公室(OIG)近期的一份報告發現,在所選郡縣中,約有 1/3 的行為健康服務提供者服務於 Medicare、Medicare Advantage 或 Medicaid 計畫的病患。提供者短缺也解釋了行為健康體系使用率偏低的原因:僅有 8% 的 Medicaid 參保者,以及不到 4% 的 Medicare 與 Medicare Advantage 參保者接受行為健康服務。

  • Acadia is dedicated to serving the needs of Medicare and Medicaid patients, as well as all other patients who come to us for care. For example, Acadia has 10 facilities that serve Medicare and Medicaid beneficiaries in the top 20 underserved counties cited by OIG in the study just referenced. We believe there are significant opportunities ahead for Acadia to extend our market reach to serve even more patients in 2024.

    Acadia 致力於滿足 Medicare 與 Medicaid 病患的需求,以及所有前來就醫的其他病患。舉例而言,在 OIG 於前述研究中列出的前 20 個醫療資源最不足的郡縣中,Acadia 有 10 家機構服務 Medicare 與 Medicaid 受益人。我們相信,2024 年 Acadia 在擴大市場觸及範圍、服務更多病患方面,仍有顯著機會。

  • Our strategic priorities will focus on accelerating facility growth, expanding services across the care continuum, strengthening our core capabilities and strategically leveraging technology to enhance patient care and improve clinical outcomes, all with a focus on delivering the highest quality patient care.

    我們的策略重點將聚焦於加速機構成長、在照護連續體上擴展服務、強化核心能力,並策略性運用科技以提升病患照護與改善臨床結果,所有作為皆以提供最高品質的病患照護為核心。

  • We're well positioned to meet our objectives with our impressive scale and proven operating model across our network of 258 facilities. The financial strength to support our continued growth and over 23,500 committed employees and clinicians, who work hard every day to address the nation's critical need for safe quality treatment for mental health and substance use issues.

    憑藉我們在 258 家機構網絡中的可觀規模與經驗證的營運模式,我們已具備良好條件以達成目標;同時也擁有支持持續成長的財務實力,以及超過 23,500 名投入的員工與臨床人員,他們每天努力回應全國對安全且高品質的心理健康與物質使用問題治療之迫切需求。

  • At this time, I will now turn the call over to Heather to discuss our financial results for the quarter.

    接下來,我將把電話會議交給 Heather,請她說明本季的財務結果。

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Thanks, Chris, and good morning, everyone. Our first quarter financial performance reflects continued growth across our business and a solid start to the year. We reported $768.1 million in revenue for the quarter, representing an increase of 9.1% over the first quarter of last year. As Chris discussed, we experienced certain headwinds in the quarter that affected our same-store revenue and patient day growth by approximately 150 basis points.

    謝謝你,Chris,各位早安。我們第一季的財務表現反映出業務持續成長,並為今年奠定穩健開局。本季我們營收為 7.681 億美元,較去年第一季成長 9.1%。如 Chris 所述,本季我們遭遇若干逆風,使同店營收與病患日成長約受到 150 個基點的影響。

  • Despite this, we drove same facility revenue growth of 9.2% over the first quarter of 2023, including a 6.9% increase in revenue per patient day and a 2.2% increase in patient days. Adjusted EBITDA for the first quarter of 2024 increased 14.9% over the prior year to $173.9 million.

    儘管如此,我們仍推動同機構營收較 2023 年第一季成長 9.2%,其中每病患日營收增加 6.9%,病患日增加 2.2%。2024 年第一季調整後 EBITDA 較去年同期成長 14.9%,達 1.739 億美元。

  • Adjusted EBITDA margins expanded by over 100 basis points over the prior year's first quarter to 22.6%, a reflection of strong cost control efforts particularly on the labor line. Adjusted income attributable to Acadia shareholders per diluted share was $0.84, up 12% from the prior year.

    調整後 EBITDA 利潤率較去年第一季擴大逾 100 個基點至 22.6%,反映出強勁的成本控管努力,尤其是在勞動成本項目。歸屬於 Acadia 股東的調整後每股稀釋盈餘為 0.84 美元,較去年成長 12%。

  • Consistent with previous periods, adjustments to income for the first quarter of 2024 include transaction, legal and other costs and related income tax effects of all items. We continue to focus on maintaining a strong financial position, providing the flexibility to deploy capital and make strategic investments in our business that offer the greatest return.

    與以往期間一致,2024 年第一季對淨利的調整項目包括交易、法律及其他成本,以及所有項目的相關所得稅影響。我們持續專注於維持強健的財務狀況,以保有資本配置彈性,並對能帶來最大回報的業務領域進行策略性投資。

  • As of March 31, 2024, we had $77.3 million in cash and cash equivalents and $371.5 million available under our $600 million revolving credit facility, with a net leverage ratio of approximately 2.5x (sic) [2.6x].

    截至 2024 年 3 月 31 日,我們持有 7,730 萬美元的現金及約當現金,並在 6 億美元的循環信貸額度下尚有 3.715 億美元可用,淨槓桿比率約為 2.5 倍(原文如此)[2.6 倍]。

  • Moving on to our outlook for 2024. As noted in our press release, we have affirmed our previously announced 2024 guidance, which includes revenue in the range of $3.18 billion to $3.25 billion, adjusted EBITDA in the range of $730 million to $770 million, adjusted earnings per diluted share in the range of $3.40 to $3.70. And total bed additions, excluding acquisitions, of approximately 1,200 beds.

    接著談 2024 年展望。如我們在新聞稿中所述,我們確認先前公布的 2024 年指引不變,包括:營收介於 31.8 億至 32.5 億美元;調整後 EBITDA 介於 7.30 億至 7.70 億美元;調整後每股稀釋盈餘介於 3.40 至 3.70 美元;以及不含併購在內的總床位新增約 1,200 床。

  • Please note that our guidance includes onetime payments from a state of approximately $10 million or $0.09 per diluted share for the year, of which approximately $7 million or $0.06 per diluted share was received in the first quarter of 2024, in line with our prior expectations.

    請注意,我們的指引包含來自某州的一次性付款,全年約 1,000 萬美元或每股稀釋 0.09 美元;其中約 700 萬美元或每股稀釋 0.06 美元已於 2024 年第一季收到,符合我們先前的預期。

  • Also as a reminder, the company's guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or nonrecurring legal settlements expense.

    另外提醒,公司指引不包含任何未來併購、處分、交易、法律及其他成本,或非經常性法律和解費用的影響。

  • With that, operator, we're ready to open the call for questions.

    以上,接線員,我們準備開放提問。

  • Operator

    Operator

  • (Operator Instructions) We will now take our first question, which will come from Scott Fidel with Stephens.

    (接線員指示)我們現在開始第一個問題,來自 Stephens 的 Scott Fidel。

  • Scott J. Fidel - MD & Analyst

    Scott J. Fidel - MD & Analyst

  • First question, just in the context of some of the volume headwinds that you did cite in the first quarter and also I talked about intra-quarter. Just interested in sort of how you're thinking about the achieving of the full year revenue guidance? Is there a particular sort of area of the range that you're comfortable with in terms of the low end, the midrange, the higher end?

    第一個問題,針對你們確實提到的第一季量能逆風,以及我也聽到你們談到季內的情況。我想了解你們如何看待達成全年營收指引?在區間上,你們對低端、中位或高端是否有特別較有把握的範圍?

  • And then also if you can talk about how you're expecting volumes and patient days to sort of ramp now from the first quarter over the balance of the year?

    另外,也請談談你們預期量能與病患日將如何從第一季開始,在今年剩餘期間逐步回升?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Great. Scott, thanks for the question. This is Chris. I'll start and maybe let Heather pick up on some of your questions on guidance. But maybe just a little bit of backdrop on volume. As we had previously discussed, January got off to a little bit slower than expected start coming out of the holiday season.

    很好。Scott,謝謝你的問題。我是 Chris。我先回答,然後也許讓 Heather 接著補充你關於指引的一些問題。不過先提供一些量能的背景。如我們先前討論過的,1 月在假期季結束後的開局比預期稍慢一些。

  • And then we saw a really nice improvement in February and certainly into March. And we felt really good about where we stood at that point. As we approach the back half of March, we began to see some softness in volumes. And it's, of course, normal for us to experience lower volumes during holidays and school breaks as our patients spend more time with their families.

    接著我們在 2 月、尤其進入 3 月時看到相當不錯的改善,當時我們對所處位置感到很有信心。當我們接近 3 月下半月時,開始看到量能有些轉弱。當然,在假期與學校放假期間,我們通常會出現較低的量能,因為病患會花更多時間與家人相處,這對我們而言是正常的。

  • However, what we found was an extended period of slower admissions in between spring break and Easter, which was earlier than usual, that being Easter at the end of March this year. So while we bake normal holiday seasonality into our outlook, what we experienced with significantly stronger seasonality in March really due to this dynamic.

    然而,我們發現的是,在春假與復活節之間出現了一段較長期間的入院放緩,而今年復活節比往年更早——今年是在三月底。因此,雖然我們在展望中已納入正常的假期季節性因素,但我們在三月所經歷的顯著更強季節性,確實是由於這個動態所致。

  • We also had 2 markets, where government facilities opened access to new behavioral beds. And this resulted in a temporary slowdown in admissions to several of our military specialty programs in those markets toward the end of the quarter as those new beds were filled. We're already well on our way back to building back census at those facilities, and we expect to be back on track by the end of the second quarter.

    我們也有兩個市場,政府機構開放了新的行為健康床位。這使得在季度末、當這些新床位被填滿時,我們在這些市場的數個軍方專科計畫入院出現了暫時性的放緩。我們已經在積極恢復並重建這些機構的住院人數(census),並預期在第二季末回到正軌。

  • The issues that weighed on volumes in March, while we were certainly frustrating or distinct issues that we just don't expect to have a lasting impact. We've seen consistent improvement in volumes over the course of April. We expect to be back on track by the end of the second quarter. We continue to expect mid-single-digit same-store patient day growth in the second half of the year.

    三月影響量能的問題,雖然確實令人沮喪,且屬於我們不預期會造成長期影響的特殊因素。四月以來,我們已看到量能持續改善。我們預期在第二季末回到正軌。我們仍預期下半年同店病患日(patient day)成長為中個位數。

  • And what gives us confidence in the back half of the year is that we really start to see a benefit from the ramp and a number of the bed additions and the JVs that we put in place last year, as well as the expansion plans for this year.

    而讓我們對下半年有信心的是,我們將真正開始看到去年所推動的一系列床位新增與合資(JV)逐步爬坡帶來的效益,以及今年的擴張計畫。

  • Heather, anything you want to add from there?

    Heather,你還想補充什麼嗎?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Yes, sure. Maybe I'll just pick up on the questions around sort of what we expect to see in the following quarters. I mean, as you know, we don't provide quarterly guidance, except for the first quarter amounts that we issue, but we did experience these issues towards the end of March, and that resulted in a little bit of a slower start to the month of April.

    好的,當然。也許我先接續回答關於我們預期未來幾季會看到什麼的問題。如你所知,我們不提供季度指引,除了我們發布的第一季金額之外;但我們確實在三月底遇到這些問題,這也導致四月初的起步稍微慢了一些。

  • So we'll still have a similar drag to second quarter in the same-store growth numbers. Just recall that our Specialty Facilities have a longer length of stay. It's usually about 28 days or longer. And so you get a little bit of a lag effect whenever you have a delay in admissions for patient days.

    因此,在第二季的同店成長數字上仍會有類似的拖累。請記得,我們的專科機構住院天數較長,通常約 28 天或更久。因此,只要入院延後,病患日就會出現一些滯後效應。

  • And then if I think about the full year, as we discussed in February, our guidance already contemplated that we would have a little bit slower start to the year at our sort of slightly below our mid-single-digit target. And obviously, first quarter finished a little bit below that expectation. And then the knock-on effect that I just mentioned will have a little bit of a slower start to second quarter than we previously would have assumed.

    再談到全年,如同我們二月討論的,我們的指引本來就已考量到年初會稍微慢一些,略低於我們中個位數的目標。顯然,第一季的結果比該預期再低一點。而我剛提到的連鎖效應,也會使第二季初的起步比我們先前假設的更慢一些。

  • But as Chris said, we continue to have a lot of confidence in the back half of the year, as we benefit from that ramp-up of bed expansions and JVs that we opened over the last several quarters. We have a large number of beds that will come online throughout the second half. And so that gives us a lot of confidence.

    但如 Chris 所說,我們對下半年仍非常有信心,因為我們將受惠於過去幾季開出的床位擴增與合資(JV)所帶來的爬坡。我們有大量床位會在下半年陸續啟用,因此這讓我們很有信心。

  • So while one quarter -- the first quarter volume was a little weaker than our expectations, when I look at the prior year comps and the ramp that we're seeing in beds that we've added over the last several quarters and then the new beds, of course, I think we'll be comfortably in the mid-single-digit range in the second half and within striking distance of that for the full year.

    所以,雖然第一季量能比我們預期稍弱,但當我看去年同期比較基期,以及我們過去幾季新增床位的爬坡情況,再加上即將新增的床位,我認為下半年我們會穩健落在中個位數區間,而全年也會相當接近該水準。

  • Scott J. Fidel - MD & Analyst

    Scott J. Fidel - MD & Analyst

  • Appreciate all that color. And just as a related follow-up, just appreciate all that color on the (inaudible) side. Just wondering on the rate side, on the pricing side, how things are developing so far in line with your expectations. It looked like you did have a solid pricing print in the first quarter, you did have some benefit from that onetime or you had called out. So just interested in sort of your updated views on pricing for the year relative to how you were thinking about the initial guidance?

    感謝這些補充說明。作為相關追問,也謝謝你對(聽不清)那一端的說明。我想問在費率端、定價端,目前的發展是否符合你們的預期。看起來第一季你們的定價表現不錯,也確實受惠於你們提到的一次性因素。所以想了解你們對今年定價的最新看法,相較於最初指引時的想法是否有變?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Yes. Sure. You're right. We did -- as we discussed in February, with our guidance, we did benefit from the $7 million of onetime state supplemental payments, and that was probably around 100 basis points on our same-store revenue per patient day.

    好的,當然。你說得對。我們——如同二月在指引中討論的——確實受惠於 700 萬美元的一次性州政府補充款項,這大約為我們同店每病患日收入帶來約 100 個基點的貢獻。

  • Remember, we also have CTC growth that goes into that calculation and that contributed probably around the same amount, about 100 basis points to the year-over-year patient day growth. And then when I think about those same-store comps, the first quarter does have an easier comp than the rest of the year. So we're not assuming that the year-over-year revenue per patient day growth continues at the same pace as first quarter after the rest of the year.

    也請記得,我們還有 CTC 的成長納入該計算,這對年對年每病患日成長的貢獻大概也差不多,約 100 個基點。再者,若看同店比較基期,第一季的比較基期比全年其餘季度更容易一些。因此,我們並未假設在今年其餘時間,每病患日收入的年對年成長會以第一季同樣的速度持續。

  • And just taking you back to our guidance that we put out in February for the full year, we talked about revenue per patient day in the mid-single-digit range, and that hasn't changed.

    回到我們二月發布的全年指引,我們提到每病患日收入在中個位數區間,這點沒有改變。

  • Operator

    Operator

  • And our next question will come from Whit Mayo with Leerink Partners.

    下一題將由 Leerink Partners 的 Whit Mayo 提問。

  • Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst

    Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst

  • Can you maybe comment a little bit on closures or divestitures in the quarter, it looks like the prior year comp was a little bit lower than we expected?

    你們能否稍微談一下本季的關閉或資產剝離?看起來去年同期的比較基期比我們預期的要低一些。

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Yes. If you think about what affected the quarter with -- if you recall, we had 4 facilities that we closed last year throughout the year. And those would have certainly been in Q1 last year but not in Q1 of this year. Three of those were in the Specialty business and then one was in the acute side. And then we had one other closure in Q1 of this year on the acute side.

    好的。若你回想一下影響本季的因素——去年我們在全年期間關閉了 4 家機構。這些在去年第一季仍會納入,但今年第一季就不在了。其中 3 家在專科業務,另 1 家在急性照護端。另外,今年第一季我們在急性照護端還有 1 家機構關閉。

  • Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst

    Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst

  • Okay. Other question I have is we're going to get the physician fee schedule out, I guess, in the next month or so, and there's probably going to be some language or discussion around the CTC, OTP business. Just curious if you have any insight perspective thoughts around like what we should expect when you put your policy regulation had on? Any comments would be helpful.

    好的。我另一個問題是,我們大概在接下來一個月左右會看到醫師費用表(physician fee schedule)發布,裡面可能會有一些關於 CTC、OTP 業務的文字或討論。想請教你們是否有任何洞見或觀點:如果你們戴上政策/法規的帽子,覺得我們應該預期看到什麼?任何評論都會有幫助。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • This is Chris. You're referring to the CTC business specifically?

    我是 Chris。你指的是特別針對 CTC 業務嗎?

  • Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst

    Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst

  • Yes. Yes. Just like in reference, like are they going to look at rebasing the bundle? Just any commentary or thoughts you have from your policy people around like what we may see or expect?

    是的,是的。比如說,他們是否會考慮重新訂定(rebasing)這個組合支付(bundle)?就想聽聽你們政策團隊對於我們可能會看到或應該預期什麼,有沒有任何評論或想法。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes, I would say, overall, we're just from the -- on the CTC front, we're just not expecting anything material. Samsung HHS have made some favorable rule changes just regarding the regulation of CTC clinics in their recent rule update. And I think there were really 3 main areas of positive change on that.

    是的,我會說整體而言——就 CTC 這一端——我們不預期會有任何重大的變動。HHS 在近期的規則更新中,針對 CTC 診所的監管做出了一些有利的規則調整。我認為主要有三個正向改變。

  • One was just continuing take-home flexibilities. There was also one around the ability to use telehealth more broadly. And the third was just enablement of small-format medication units that can allow the full range of OTP services. But other than that, it would be just speculative.

    第一是延續可攜回(take-home)的彈性。第二是更廣泛地允許使用遠距醫療(telehealth)。第三是允許小型化的給藥單元(small-format medication units),使其能提供完整範圍的 OTP 服務。除此之外,就只能算是推測。

  • Operator

    Operator

  • And our next question will come from Brian Tanquilut with Jefferies.

    下一題將由 Jefferies 的 Brian Tanquilut 提問。

  • Brian Gil Tanquilut - Senior Equity/Stock Analyst

    Brian Gil Tanquilut - Senior Equity/Stock Analyst

  • Maybe, Chris, first question for me. Just as we think about -- sorry, legislative efforts to make changes to methadone treatment access, maybe just curious to hear your thoughts again on (inaudible) implemented these changes would affect your business? And then maybe tying that to maybe comments from the DEA recently on other drugs used to treat opioid addiction and how that's tracking in terms of expanding access for folks who are addicted to opioids.

    Chris,我的第一個問題是:當我們思考——抱歉,是立法層面試圖改變美沙酮治療可近性的努力時——想再聽聽你的看法,(聽不清)若這些變更落實,會如何影響你們的業務?另外也想把這點連結到 DEA 最近對其他用於治療阿片類成癮藥物的評論,看看在擴大阿片類成癮者可近性方面,目前進展如何。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. No, thank you for the question. And I would say that overall, we continue to be very strong proponents of increasing access to OUD care. And there obviously are a number of policy proposals out there. We have, I think, done an excellent job in our CTC business of focusing on patient quality. CARF is the regulatory body that measures the OUD players.

    好的,謝謝你的問題。我會說整體而言,我們仍然非常支持提升 OUD 照護的可近性。市場上確實有許多政策提案。我們在 CTC 業務上,我認為在聚焦病患品質方面做得非常出色。CARF 是衡量 OUD 相關業者的認證/監管機構。

  • And our quality scores have continued to be in the 98-plus percent range. And so we continue to believe that our focus on quality, our focus on patient outcomes, where we find that 90% of our -- 80-plus percent of our patients are illicit opioid free within 6 months of treatment.

    而我們的品質分數持續維持在 98% 以上。因此我們仍相信,我們對品質的重視、對病患治療結果的重視——我們看到在治療 6 個月內,90% 的我們——80% 以上的病患已不再使用非法阿片類藥物。

  • And then we've operationally put in all sorts of patient very positive changes over the course of the last 6 months, including significantly reducing wait times, and our patient satisfaction is really up as well. So with all those things together, we just continue to feel like we want to continue to expand access. We're going to continue to make significant investments in this business. And we'll continue to monitor the legislation and continue to work with lawmakers and expanding access and moving that along.

    接著,在過去 6 個月的過程中,我們在營運面推動了各式各樣以病患為中心、非常正向的改變,包括大幅縮短等候時間,而我們的病患滿意度也確實顯著提升。因此,綜合以上各項因素,我們持續認為應該要繼續擴大可近性。我們將持續在這項業務上進行重大投資。我們也會持續關注相關立法,並持續與立法者合作,推動擴大可近性並促進相關進展。

  • Brian Gil Tanquilut - Senior Equity/Stock Analyst

    Brian Gil Tanquilut - Senior Equity/Stock Analyst

  • Got it. And then maybe just any update you can share with us on litigation in New Mexico.

    了解。那麼,關於新墨西哥州的訴訟案,您是否可以分享任何最新進展?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • The only thing that I would say there, if you're referring specifically to the 6 Desert Hills case, it's just very difficult for us to comment on pending litigation, but you should know that there's much still to be tested in core, and we intend to vigorously defend the company on that case. We were served with an amended complaint on March 25, and we filed initial pleadings on April 24. And I would just say our legal team is very diligently working on developing the case.

    我在這部分唯一能說的是,如果你指的是特定的 Desert Hills 6 案,我們很難對尚在進行中的訴訟發表評論;但你應該知道,案件在法院中仍有許多事項有待釐清,而我們也打算在該案中積極為公司辯護。我們在 3 月 25 日收到修正後的起訴狀,並於 4 月 24 日提交初步答辯文件。我只能說,我們的法務團隊正非常勤勉地投入案件的建構與準備。

  • Operator

    Operator

  • And our next question will come from Andrew Mok with Barclays.

    下一題將由 Barclays 的 Andrew Mok 提問。

  • Andrew Mok

    Andrew Mok

  • First, I just wanted to follow up on the volume trends in the quarter. So it sounds like the quarter was bookended by seasonal factors in January and March and further impacted by the new military facility openings. Were all 3 of those items expected in the quarter and just had a greater-than-expected impact? Or were any of those items truly a surprise, maybe the military facility openings, you didn't have visibility into? Can you just clarify that first?

    首先,我想追問一下本季的量能趨勢。聽起來本季在 1 月與 3 月受到季節性因素影響,並且又受到新的軍方設施開張的進一步衝擊。這三項因素在本季原本都在預期之內、只是影響程度超出預期嗎?還是其中有任何一項其實是意外,例如軍方設施開張你們事前沒有掌握?能否先請你釐清一下?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Yes, sure. I would say those were not expected to the extent that we saw them. The first thing I would tell you is that the seasonality, the difference between spring break or the interval between spring break and Easter. Certainly, we would have anticipated normal seasonality around each of those events.

    好的,當然。我會說,我們並未預期會以我們實際看到的程度發生。首先我想說的是季節性,也就是春假與復活節之間的間隔差異。當然,我們會預期在這兩個事件各自周邊出現正常的季節性波動。

  • But the difference was the interval between the 2. And so of course, we anticipate the events, but we didn't anticipate that significant difference in the interval between the 2. In terms of the few facilities with the Military business, those beds opened earlier -- at the other facilities opened earlier in the quarter, but we didn't see any impact of that for several weeks. And so that did sort of pop up as a surprise to us in the second half of March.

    但差異在於兩者之間的間隔。因此,我們當然預期這些事件本身,但沒有預期兩者之間的間隔會出現那麼顯著的差異。至於少數涉及軍方業務的設施,那些床位在本季較早時點就已於其他設施開放,但我們在接下來數週並未看到任何影響。因此,這確實在 3 月下半月以一種出乎意料的方式浮現。

  • And that's just really thinking about those facilities, it was more heavily weighted to the Specialty business. And keep in mind that those have a longer length of stay. And so it takes a little bit longer for sort of a downturn in admissions or a shortfall to flow through. And so we would not have anticipated that either. Those are really the 2 things that came up in the back half of March that we didn't anticipate.

    而就那些設施來看,影響其實更偏向 Specialty(專科)業務。請記得,這些個案的住院天數較長,因此入院量下滑或缺口要反映到數據上會需要更長時間。所以我們也不會預期到這一點。這兩件事確實是在 3 月下半段出現、且是我們未事先預期的。

  • Andrew Mok

    Andrew Mok

  • Got it. Okay. And then your SWB per patient day in the quarter, I think, finished below 5% despite the headwinds from patient days. So anything in particular that helped to drive the strong results there and given the normalizing patient day trends, we should be seeing in 2Q and 3Q, is it reasonable that SWB per patient day continues to track below 5%?

    了解。好的。接著,本季你們的 SWB(薪資與福利)每病患日,我記得即使在病患日數帶來逆風的情況下,最後仍低於 5%。是否有任何特別因素推動了這樣的強勁表現?另外,考量到 2Q 和 3Q 病患日趨勢應會正常化,是否合理預期 SWB 每病患日仍會持續低於 5%?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Yes, you're right. It did track below the 5%, which is, as you recall, what we discussed last quarter and where those levels we anticipate staying and we see base wage inflation coming in line with SWB per patient day as well. We continue to focus on all those things that we have been focusing on for the last, I would say, 12 to 18 months in regards to employee engagement and retention, and we're seeing the benefits of that come through.

    是的,你說得對,確實低於 5%。如你所記得的,這也是我們上季討論過的水準,並且是我們預期會維持的區間;我們也看到基本薪資通膨正逐步與 SWB 每病患日的趨勢一致。我們持續聚焦在過去大約 12 到 18 個月一直在做的事情,也就是員工敬業度與留任方面的努力,而我們正看到這些投入帶來的效益逐步反映出來。

  • We will expect that, that same level would continue throughout the year, and we'll keep a very close eye on it, as I'm sure you can appreciate, as any company that operates in multiple geographies across the country.

    我們預期同樣的水準會在全年持續,我們也會非常密切地關注這點——我相信你能理解,對於一家在全國多個地區營運的公司而言尤其如此。

  • We still have some pockets with challenges, but we feel really good about what we've been doing and the investments we've made so that we can have a great start to 2024. So maybe to wrap that up for the full year for '24, we still expect that base wage inflation. And SWB per patient day will reflect that normalized rate.

    我們仍有一些區域面臨挑戰,但我們對於目前所做的事情以及所投入的投資感到非常有信心,這也讓我們能在 2024 年有一個很好的開始。總結來說,就 2024 全年而言,我們仍預期基本薪資通膨,而 SWB 每病患日也將反映該正常化的增速。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • And just maybe to add in on base wage inflation. I mean we clearly saw the high watermark in the fourth quarter of 2022 and have been, as Heather said, just very focused on our efforts around employee engagement, around retention, working with the local market operators and have been able to continue to bring that down to ending the year under 5%.

    另外補充一下基本薪資通膨。我們很清楚在 2022 年第四季看到高點,之後如 Heather 所說,我們一直非常專注於員工敬業度與留任的相關工作,並與各地市場的營運團隊合作,得以持續把增幅降下來,並在年底降至 5% 以下。

  • And as Heather said, likewise, with the SWB per patient day also being under 5%, we see that trend continuing.

    而如 Heather 所說,同樣地,SWB 每病患日也在 5% 以下,我們認為這個趨勢會持續。

  • Operator

    Operator

  • Our next question will come from Ben Hendrix with RBC Capital Markets.

    下一題將由 RBC Capital Markets 的 Ben Hendrix 提問。

  • Benjamin Hendrix - Assistant VP

    Benjamin Hendrix - Assistant VP

  • I just wanted to get some follow-up commentary on your Partial Hospital Program and IOPs, kind of information on where they fit in, in terms of your development strategy going forward? Should we think about those as just an extension of the Acute platform? Or could this be a new leg of the stool in terms of your business line segmentation?

    我想就你們的部分住院計畫(PHP)與密集門診計畫(IOP)再追問一些看法,特別是它們在你們未來發展策略中的定位?我們應該把它們視為急性照護平台(Acute platform)的延伸?還是這可能會成為你們業務線分部上的「第三支柱」?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. Thanks, Ben. We really believe that the impact of PHP/IOP on the clinical outcomes of our patients can really be significant. The vast majority of both our Acute and our Specialty patients are indicated for PHP or IOP, as a step-down therapy post discharge.

    是的,謝謝你,Ben。我們確實相信 PHP/IOP 對病患臨床結果的影響可以非常顯著。我們的 Acute(急性)與 Specialty(專科)病患中,絕大多數在出院後作為降階治療(step-down therapy)都適用 PHP 或 IOP。

  • And we see the clinical outcomes from that and that continuity of care being extremely important to maintaining those strong outcomes. Given the value to the patients, we have begun to build these programs out in some form at or near most of our Acute and Specialty facilities. But for multiple reasons, we continue to see opportunity for growth in the future. I mean I think there is opportunity in expansion in the number of PHP/IOP programs per facility.

    我們也看到這樣做帶來的臨床結果,以及照護連續性對維持良好結果的重要性。基於對病患的價值,我們已開始在我們多數 Acute 與 Specialty 設施內或附近,以某種形式建置這些計畫。但基於多項原因,我們仍看到未來的成長機會。我認為每個設施可擴增的 PHP/IOP 計畫數量本身就有擴張空間。

  • We have real variability across the company in terms of how many tracks of PHP/IOP we have at a given facility. We also look at each of our facilities for opportunities to just better serve our patients by adding more programs. So adult versus adolescent, women's focus, evening versus daytime and just PHP versus IOP in general.

    在公司內部,各設施在 PHP/IOP 的「軌道/組別」(tracks)數量上差異很大。我們也會檢視每一個設施,尋找透過增加更多計畫來更好服務病患的機會,例如成人對青少年、女性取向、夜間對日間,以及整體而言 PHP 對 IOP 的配置。

  • So I think just overall, increasing the share of the clinically eligible patients who benefit from PHP/IOPs in the best interest of the patients, and we need to be more intentional about ensuring that continuity of care. And we really try to address the needs of the community and how we can best impact that continuity of care.

    因此我認為整體來說,提高符合臨床資格的病患中能從 PHP/IOP 受益的比例,符合病患的最佳利益;而我們也需要更有意識地確保照護的連續性。我們也確實努力回應社區需求,並思考如何能對這種照護連續性產生最佳影響。

  • So we are opening new facilities. We're working through licenses and certifications. We're looking at what the most appropriate programs are to add initially. And we're also looking hard at the ability to cross-refer across our Acadia lines of business where possible.

    因此我們正在開設新設施,推進執照與認證流程,評估最適合一開始導入的計畫類型。同時,我們也在積極評估在可行之處,於 Acadia 各業務線之間進行交叉轉介的能力。

  • As we've said before, we know that 70% of our Specialty patients that present also have an underlying OUD diagnosis. And so that cross referral is also very important. So we just see this pathway as something that has a lot of opportunity for patients because of the strong clinical outcomes and we intend to capitalize on it.

    如我們先前所說,我們知道有 70% 的 Specialty 病患在就診時同時具有潛在的 OUD(鴉片類物質使用障礙)診斷,因此交叉轉介也非常重要。總之,我們認為這條照護路徑因其強勁的臨床結果,對病患而言具有很大的機會,而我們也打算把握並加以發揮。

  • Benjamin Hendrix - Assistant VP

    Benjamin Hendrix - Assistant VP

  • Just a quick follow-up on the labor trend. Should we -- is there any way to quantify how much perhaps incremental hiring or recruiting costs we might see later in the year as your development pipeline plays out in the second half?

    再快速追問一下人力趨勢。隨著你們在下半年發展管線逐步落地,今年稍晚是否可能看到一些增量的招募或聘用成本?有沒有任何方式可以量化?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • I don't know that we'll quantify the amount, but I can tell you that we have assumed that sort of the normal course of business will continue as we've seen it sort of throughout the back half of last year and then continuing into Q1. So what you're asking is if we're assuming an elevated level? And the answer is no.

    我不確定我們是否會量化這個金額,但我可以告訴你,我們的假設是「正常的營運狀態」會延續,也就是如同我們在去年下半年看到的情況,並延續到第一季。你問的是我們是否假設會出現偏高的水準?答案是否定的。

  • Operator

    Operator

  • Our next question will come from A.J. Rice with UBS.

    下一個提問將由瑞銀(UBS)的 A.J. Rice 提出。

  • Albert J. William Rice - Analyst

    Albert J. William Rice - Analyst

  • Maybe first just to ask, we haven't talked in a while about the opioid settlement and how those dollars states or maybe whether any of that's flowing to your areas of focus and to the extent it is, is that in little more healthy rate updates? Or is it in other areas? Any comments on that?

    或許先請教一下,我們有一段時間沒有談到阿片類藥物和解金,以及這些資金各州的使用情況,或是否有任何資金流向你們的重點領域;若有,是否反映在較健康的費率更新上?還是用在其他領域?對此有何評論?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. Thanks, A.J. This is Chris. I'll take that one. I think just to step back, the settlement funding continues to trickle along. So again, of the roughly $50 billion of funds available, approximately $4.5 billion have actually been distributed to date. And just to give you some context on that, in mid-2023, we were at $3 billion.

    是的,謝謝你,A.J.。我是 Chris,我來回答。我想先退一步看,和解資金仍在持續零星撥付。因此,在約 500 億美元可用資金中,截至目前實際已分配約 45 億美元。提供一些背景:在 2023 年年中,我們約為 30 億美元。

  • So still under 10% of funds have actually been distributed to the states. And then obviously, from the states, they have to be deployed to individual counties. We see a number of states leading the way on this, and we continue to position ourselves just given the very strong clinical outcomes that we're seeing in our CTC business to participate in those grant funding opportunities and to win.

    所以實際分配給各州的資金仍不到 10%。接著當然,各州還必須再部署到各個郡縣。我們看到有不少州在這方面領先推進;而我們也持續定位自己,鑑於我們在 CTC 業務中看到非常強勁的臨床成效,來參與並贏得這些補助資金機會。

  • And so we -- the best recent award settlement example that I can give you is that in Q1, we were awarded Funding by Opportunity in Tennessee, and we were actually awarded -- I think there were over 400 different applicants, and we were one of the top recipients. We were awarded $6 million in Funding by the Tennessee Opioid Abatement Council.

    因此,我們——我能給你的最近一個最佳和解金獲獎例子是:在第一季,我們在田納西州獲得「Funding by Opportunity」的資助,而且我們實際上獲得——我想當時有超過 400 個不同的申請者,我們是主要受款者之一。我們獲田納西州阿片類藥物減害委員會(Tennessee Opioid Abatement Council)核發 600 萬美元資金。

  • And the funds there are going to meaningfully contribute to treatment to underserved populations, which is really what the focus of the grant was hiring peer support personnel to help patients go through their recovery and just overall helping patients stay in treatment, particularly by covering expenses associated with social determinants, such as transportation.

    而這些資金將對服務資源不足族群的治療做出實質貢獻,這也正是該補助的重點:聘用同儕支持人員協助病患走過復原歷程,並整體上協助病患持續留在治療中,特別是透過支付與社會決定因素相關的費用,例如交通。

  • And so of that $6 million, we're right now -- we have won that $6 million component. We're in the contracting phase. Funds will take a few months to be dispersed, but we expect this to be $2 million a year over a 3-year period. So hopefully, that's helpful.

    因此,就這 600 萬美元而言,我們目前——我們已贏得這 600 萬美元的部分,正處於簽約階段。資金撥付還需要幾個月,但我們預期將在 3 年期間每年約 200 萬美元。希望這些資訊有幫助。

  • Albert J. William Rice - Analyst

    Albert J. William Rice - Analyst

  • Yes, that's good. And then on -- maybe on the development and acquisition pipeline. There's been some recent scrutiny, both in some of the articles that have been written about opioid use disorder, et cetera, as well as in some of the congressional activity around private equity and in health care generally, and questioning that.

    是的,這很好。接著——也許談談開發與併購管線。最近外界有一些審視,無論是在一些關於阿片類藥物使用障礙(opioid use disorder)等的文章中,或是在國會對私募股權以及整體醫療保健領域的一些活動與質疑。

  • I wondered whether -- is that -- because I know private equity is quite active in some of your spaces. Has that impacted anything both created any new opportunities for you, changed any way the competitiveness of transactions you're looking at?

    我想知道——這是否——因為我知道私募股權在你們的一些領域相當活躍。這是否對任何事情造成影響:是否為你們創造新的機會,或改變你們正在評估交易的競爭態勢?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes. I would -- thanks, A.J. I would say to start that this has been a very difficult operating environment for a very fragmented industry of various players in the OUD space. So you'll recall a year ago at this time, we were so focused on Medicaid redetermination and made significant investments in putting a dedicated 800 hot line in place, putting kiosks in place for our patients actively preparing to help them manage through the complexities of redetermination, which I think we have done -- our team has done an excellent job on.

    是的。我——謝謝你,A.J.。我會先說,對於 OUD 領域中由各式玩家構成、且高度分散的產業而言,這一直是非常艱難的營運環境。你會記得一年前的這個時候,我們非常專注在 Medicaid 重新認定(redetermination),並投入大量資源:設置專用的 800 免付費專線、為病患設置自助服務機(kiosks),積極準備協助他們因應重新認定的複雜性;我認為我們的團隊在這方面做得非常出色。

  • But that has been really challenging for a number of players. And I think we are increasingly seen as an acquirer of choice. So we've seen interest from a lot of smaller clinics. And the 3 clinics that we were recently -- that we recently acquired in North Carolina, I think are illustrative of that, they're now fully operational, strong track record of positive patient outcomes.

    但這對許多業者而言非常具挑戰。我認為我們愈來愈被視為首選收購方。因此,我們看到許多小型診所表達興趣。而我們最近在北卡羅來納州收購的 3 家診所,我想就很能說明這點:它們現在已全面運作,且在病患正向治療結果方面有良好紀錄。

  • But putting those on our chassis, we're able to serve these patients even more efficiently, particularly given some of the advances in technology that we've made there. So we're now in North Carolina, we've expanded from 7 CTCs, with these 3 additions to 10, we're a real market leader in the state there. And we continue to think that there will be additional M&A opportunity, particularly from -- in this space that remains so fragmented.

    但把這些診所納入我們的平台後,我們能更有效率地服務這些病患,特別是考量到我們在技術方面所做的一些進展。因此,我們在北卡羅來納州已從 7 家 CTC,隨著新增這 3 家擴展到 10 家,成為該州真正的市場領導者。我們也持續認為仍會有更多併購機會,尤其是在這個仍高度分散的領域。

  • I think your question may also tie to some of the larger private equity scale players. And we really have not seen a lot of activity on that front, but it's just difficult to say how that will continue through the year. But we -- from an attractiveness of these smaller opportunities, we continue to be very positive on those and continue to pursue those.

    我想你的問題也可能牽涉到一些規模較大的私募股權平台型業者。就這方面而言,我們確實沒有看到太多活動,但很難說今年接下來會如何發展。不過——就這些較小型機會的吸引力而言,我們仍然非常正面,並會持續追求。

  • Operator

    Operator

  • And our next question will come from John Ransom with Raymond James.

    下一個提問將由 Raymond James 的 John Ransom 提出。

  • John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

    John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

  • Some of your provider -- I guess they're not peers, but other providers have called out kind of the Medicaid to HICS as being a thing in their results. Are you seeing anything with either health exchange enrollment or Medicaid to call out so far this year?

    你們的一些同業——我想他們不算直接同業,但其他服務提供者提到,他們的結果中有提到 Medicaid 轉到 HICS 這件事。你們今年到目前為止,是否看到任何與健康保險交易所投保(health exchange enrollment)或 Medicaid 相關、值得特別提出的情況?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Hi John. No, we're not. I think you're referring to as patients move from Medicaid, maybe through the redetermination process and on to the exchanges, are we seeing any impact as a result of that. And we're not. It's a very, very small portion of our patients that would be in that category. Those are mostly in the CTC business. But again, it's a very, very small percentage of patients.

    嗨,John。沒有,我們沒有。我想你指的是病患從 Medicaid 可能透過重新認定流程轉到交易所時,我們是否因此看到任何影響。我們沒有。屬於那一類的病患在我們這裡占比非常、非常小。那些多半在 CTC 業務中,但同樣地,占比非常、非常低。

  • John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

    John Wilson Ransom - MD of Equity Research & Director of Healthcare Research

  • Okay. And then my follow-up is just going back to corporate overhead. It's running about $26 million higher than it was in 2022 to 2023 and then it's elevated, again, although at a slower pace. Can you just give us an outlook for corporate overhead for the remainder of the year? And just kind of remind us where those dollars went to, whether it's technology or people or other?

    好的。那我的追問是回到公司管理費用(corporate overhead)。從 2022 到 2023 年大約增加了 2,600 萬美元,之後又再提高,雖然增速較慢。你能否就今年剩餘期間的公司管理費用給我們一個展望?也請提醒我們這些資金主要用在哪裡,是技術、人員,或其他?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Yes, sure. I'll kick that off, and then Chris may want to jump in on the last part of your question. So you're right, we did see a sequential increase of about 20 basis points. But on a year-over-year basis, we saw an improvement of about the same amount. And that's what I would consider the lowering of the baseline of growth there because we have really been focused on those corporate costs, but also normal seasonality from Q4 to Q1 that we typically see.

    好的,當然。我先回答,然後 Chris 可能會想補充你問題的最後一部分。你說得對,我們確實看到約 20 個基點的季比增加。但以年比來看,我們看到大約同等幅度的改善。我會把這視為成長基準的下移,因為我們一直非常專注在這些公司成本上;同時也有我們通常會看到的從第四季到第一季的正常季節性因素。

  • Couple of reasons for that. It might be merit increases or some of the differences that come in Q1 from a payroll tax perspective come into play, but that's what I would consider normal seasonality. I mean in general, we've seen the stabilization, as I mentioned, in those corporate costs, and we're starting to really see the benefit of some of those investments.

    原因有幾個,可能包括調薪(merit increases),或第一季在薪資稅(payroll tax)角度出現的一些差異,但我會把這視為正常的季節性。整體而言,如我提到的,我們已看到這些公司成本趨於穩定,而且我們開始真正看到部分投資帶來的效益。

  • Maybe just to think about how we view the balance of the year as those investments continue to pay off. And frankly, as we start to lap some of those investments from last year, we'll expect to continue to see operating leverage as we move throughout the year.

    也許從我們如何看待今年剩餘期間來思考:隨著這些投資持續產生回報,坦白說,當我們開始與去年這些投資形成可比基期(lap)後,我們預期在全年推進過程中將持續看到營運槓桿。

  • We expect that the corporate costs will stay relatively consistent, certainly as a percentage of revenues and then they'll moderate and just create that leverage. And just the last part of your question on what we've been focused on, it's across the board.

    我們預期公司成本將維持相對一致,至少以營收占比來看;接著它們會趨於緩和並帶來槓桿效應。至於你問題的最後一部分——我們的投入重點是全面性的。

  • We've, of course, invested in IT. We've invested in quality. Our Managed Care team has really been a big focus and a benefit to us, some of the marketing things that we've done. So just overall, just looking across the board, no one specific area, I would say, outpaced.

    我們當然投資了 IT,也投資了品質。我們的受管理式照護(Managed Care)團隊一直是很大的重點,也為我們帶來效益;以及我們做的一些行銷工作。總體而言,放眼各面向,我不會說有任何單一領域的增幅特別突出。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Yes, John, this is Chris. I think the only other thing I would say is just that we continue to watch this very closely. I think we also, just given the commitment that we put out at our first ever Investor Day in December of 2022, we really felt like there was too much variation across the company in terms of the way we were approaching quality and IT and just other corporate areas that we needed to make some investments, and we feel very pleased with what we've been able to do there and some of the talent that we've been able to attract, but also some of the process that we've put in place and some of the results that we're continuing to see that position us well for the future. So we'll continue to watch it moving forward.

    是的,John,我是 Chris。我想我唯一要補充的是,我們會持續非常密切地關注這件事。我也認為,考量到我們在 2022 年 12 月首次投資人日所提出的承諾,我們確實覺得公司在品質、IT 以及其他公司層面領域的做法差異過大,因此需要做一些投資。我們對目前能做到的事情以及吸引到的人才感到非常滿意,同時也對我們建立的流程,以及我們持續看到、能讓我們在未來具備良好定位的成果感到滿意。因此,我們會在未來持續關注。

  • Operator

    Operator

  • And our next question will come from Pito Chickering with Deutsche Bank.

    我們的下一個問題將由德意志銀行(Deutsche Bank)的 Pito Chickering 提出。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Sure lead up here, I know you don't give quarterly guidance, but the comments are on a slower start to April, lagging impact from the longer look of, say, patients in Specialty. Can you give us any commentary around if 2Q consensus is mismodeled?

    好的,先鋪陳一下。我知道你們不提供季度指引,但你們的評論提到 4 月開局較慢,以及例如專科(Specialty)病患就醫週期拉長所帶來的滯後影響。你們能否就第二季市場共識是否建模有誤提供一些看法?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • Yes. As you know, we don't give quarterly guidance, except for first quarter, and I really don't like to comment on consensus and how the modeling comes in. I'll just maybe reiterate, Pito, on what we said. When we think about how the quarters will play out, we think that we will have a similar drag to the beginning of 2Q, certainly on a same-store basis, just as we start to bring ourselves through the second quarter. Q1, obviously, is a little bit slower, and that's going to drive a little bit slower start to Q2, but we really have a lot in the back half of the year.

    是的。如你所知,我們不提供季度指引,第一季除外;而且我也不太喜歡評論市場共識以及模型是如何推導出來的。我可能只是再重申一下,Pito,我們先前所說的內容。當我們思考各季度將如何展開時,我們認為在第二季初期,確實會出現類似的拖累,尤其是在同店基礎上,因為我們正逐步進入第二季。第一季顯然稍微慢一些,這會帶來第二季稍慢的開局,但我們在今年下半年有很多動能。

  • Philip Chickering - Research Analyst

    Philip Chickering - Research Analyst

  • Okay. And a follow-up here. Despite the seasonal softness that you guys talked about, your EBITDA margins of 22.6% were the highest first quarter that we've seen. Is there any sort of onetime benefit that you guys saw on the cost side? Or should this be a baseline margin fee as sort of you grow from in 2024 and 2025? And besides the onetime $10 million payment, are there any new Medicaid programs started in 2024?

    好的。接著追問一下。儘管你們提到季節性走弱,你們 22.6% 的 EBITDA 利潤率卻是我們所見過最高的第一季水準。成本端是否有任何一次性利多?或者,隨著你們在 2024 與 2025 年成長,這應該可視為基準利潤率?另外,除了那筆一次性的 1,000 萬美元付款之外,2024 年是否有任何新的 Medicaid 計畫啟動?

  • Heather Dixon - CFO

    Heather Dixon - CFO

  • So maybe I'll take that in 2 parts. So in terms of EBITDA, when we set out the guidance at the beginning of the year, we said we expected to see some leverage. And so we are seeing that leverage. We're really, really pleased to see that we're outperforming in the first quarter, and that's driven largely by the SWB line, which, of course, we've been very focused on over the last 12 months.

    我可能分兩部分回答。就 EBITDA 而言,年初我們提出指引時就表示預期會看到一些營運槓桿,而我們確實正在看到這些槓桿。我們非常、非常高興第一季表現優於預期,這主要是由 SWB 這條線所帶動;當然,過去 12 個月我們一直非常專注在這一塊。

  • As we are doing the work around all of the things we've done to invest in the hiring retention, we're just seeing that, as we said earlier, continued moderated rate. But also, I think it's important to point out, we were able to really react quickly, to some of the softer volumes that we saw at the end of March.

    在我們推動並投入所有與招募與留任相關的工作時,我們正如先前所說,看到薪資成長率持續趨於溫和。不過我也認為很重要的一點是,我們能夠對 3 月底看到的一些較疲弱量能迅速做出反應。

  • And I think the team did a really good job of just managing through that. And so that gives us a lot of confidence really in the EBITDA outlook for the balance of the year. If I think about those sort of payments and what those supplemental funds look like, I think that's where you're headed. I mean some states, as you know, use this to enhance what they can pay for the Medicaid rates and really to bolster those and intending to correct for what's, frankly, historically inadequate reimbursement for keeping up with the cost of care for our patients.

    我認為團隊在管理與因應方面做得非常好。因此,這也讓我們對今年剩餘期間的 EBITDA 展望更有信心。若我再想想那些付款以及補充資金的樣貌,我想這就是你要問的方向。我的意思是,有些州如你所知,會用這些資金來提高他們能支付的 Medicaid 費率,並強化這些費率,意在修正坦白說長期以來補償不足、無法跟上我們照護病患成本的歷史問題。

  • And I know some of our peers have had some large distributions in specific states. We typically see those on a year-to-year basis, they're relatively consistent. And frankly, we just consider it part of our reimbursement as we go through.

    我知道我們的一些同業在特定州曾收到較大額的分配。我們通常每年都會看到這類款項,且相對一致。坦白說,我們只是把它視為我們在營運過程中的一部分給付(reimbursement)。

  • That said, if we have something that's outsized is a onetime payment, we'll call those out. I think we've done it a couple of times in the past. And as you mentioned, we called that out sort of for one state with our guidance that we put out earlier this year, and that was $10 million for the full year and $7 million in Q1.

    也就是說,如果有某些金額特別大、屬於一次性付款,我們會特別指出。我想過去我們也做過幾次。正如你提到的,我們在今年稍早發布的指引中,已就某一州特別說明:全年為 1,000 萬美元,其中第一季為 700 萬美元。

  • Operator

    Operator

  • And our next question will come from Sarah James with Cantor Fitzgerald.

    我們的下一個問題將由 Cantor Fitzgerald 的 Sarah James 提出。

  • Gabrielle Alexa Ingoglia - Research Analyst

    Gabrielle Alexa Ingoglia - Research Analyst

  • This is Gabie on for Sarah. I just had a quick question on what results you guys have seen from the remote monitoring at the 53 facilities that you had rolled out by the end of last year. And if you have any more plans to add more facilities?

    我是 Gabie,代 Sarah 提問。我想快速問一下:截至去年底你們已在 53 家機構導入的遠端監測,你們看到了哪些成效?以及你們是否有計畫再增加更多機構?

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Gabie, this is Chris. I'll take that one. We've seen very positive results from the remote monitoring that we've now implemented in all 53 of our Acute Facilities. This is technology that we think has been critical to ensuring that our scheduled observation rounds are taking place at the appropriate time.

    Gabie,我是 Chris。我來回答這題。我們已在 53 家急性照護機構(Acute Facilities)全面導入遠端監測,並看到了非常正面的成果。我們認為這項技術對於確保我們排定的巡視觀察(observation rounds)能在適當時間進行至關重要。

  • I think our staff has told us that they feel safer and more comfortable with this mechanism in place. Our patient experience and our patient satisfaction scores have actually gone up. And we've got an extremely positive feedback from surveyors that have come into our facilities, being able to show them the results that we've had from this monitoring, whether it's state surveyors or even talking to others across the board, just it's been very consistently positive feedback.

    我想我們的員工告訴我們,在有這套機制之後,他們感到更安全、更安心。我們的病患體驗與病患滿意度分數實際上也提升了。而且,前來我們機構的稽核人員給了我們極為正面的回饋;我們能向他們展示這套監測帶來的成果,不論是州政府稽核人員,或是與其他各方交流,回饋都非常一致地正面。

  • So we are looking at potentially expanding that even further. We've also have been investing pretty heavily in staff safety with personal alarm buttons for all of our hospital staff that we're also rolling out this year. And I think you will continue to see more of that as we look to continue to improve our overall employee engagement but also our patient satisfaction, and it's proving out.

    因此,我們正在評估是否進一步擴大導入。我們也在員工安全方面投入相當多資源,為所有醫院員工配備個人警報按鈕,並將在今年推行。我想隨著我們持續提升整體員工敬業度以及病患滿意度,你們會看到更多這類措施,而目前也正證明其成效。

  • Operator

    Operator

  • And this concludes our question-and-answer session. I would like to now turn the conference back over to Chris Hunter for any closing remarks.

    我們的問答環節到此結束。現在我想把電話會議交回給 Chris Hunter,請他做結語。

  • Christopher Howal Hunter - CEO & Director

    Christopher Howal Hunter - CEO & Director

  • Thank you. Before we end the call, I just want to again thank our committed facility leaders, clinicians and approximately 23,500 dedicated employees across the country, who've continued to work tirelessly to meet the needs of the over 75,000 patients that we treat daily and their families in a safe and effective manner and who every day exemplify our purpose as an organization to lead care with light.

    謝謝。在結束本次電話會議之前,我想再次感謝我們盡責投入的各院所領導團隊、臨床人員,以及遍布全國約 23,500 名敬業的員工;他們持續不懈地工作,以安全且有效的方式滿足我們每日治療的超過 75,000 名病患及其家屬的需求,並且每天都體現我們作為一個組織的宗旨:以光引領照護(to lead care with light)。

  • We have a strong foundation and a proven strategy for driving growth and delivering greater value to both the patients we serve and our shareholders. Thank you for being with us this morning and for your interest in Acadia. If you have additional questions today, please do not hesitate to contact us directly. Have a good day.

    我們擁有堅實的基礎,以及經驗證的策略,能推動成長並為我們服務的病患與股東創造更高價值。感謝各位今天早上與我們同在,並關注 Acadia。若你們今天還有其他問題,請隨時直接與我們聯繫。祝各位有美好的一天。

  • Operator

    Operator

  • The conference has now concluded. Thank you for attending today's presentation. You may now disconnect your lines.

    本次電話會議已結束。感謝各位參加今天的簡報。您現在可以掛斷電話線路。